Browse the evidence

GLP-1 receptor agonists (semaglutide) and dual incretin agonists (tirzepatide) achieve 15-20% total body weight loss, rivaling the efficacy of bariatric surgery.

If you have obesity, these medications offer a powerful, non-surgical path to significant weight loss (15-20%). They require a weekly injection and likely lifelong use, but they can improve metabolic health and may be more accessible than surgery for some. Discuss with your doctor if you are a candidate.

GLP-1 receptor agonists (semaglutide and tirzepatide) produce significantly greater average weight loss (14.9% and 18.5%, respectively) than physicians estimate (9.22%), and are associated with high rates of gastrointestinal side effects (80-90%) that are significantly underestimated by prescribers.

If you are prescribing GLP-1 agonists, ensure you are counseling patients on the high likelihood of gastrointestinal side effects (up to 90%) and the significant magnitude of weight loss (15-18%). Underestimating these factors leads to poor adherence and unrealistic expectations.

Health Behavior Intervention (HBI) consisting of 13 dietician-led counseling sessions over 1 year is a cost-effective strategy for managing class III obesity compared to no treatment.

For individuals with class III obesity, engaging in 13 dietician-led counseling sessions over a year is a cost-effective way to manage weight and prevent complications, especially if surgery is not an option.

Incretin medications (GLP-1 RAs and dual agonists) are the most effective class of AOMs for older adults, achieving 15-25% weight loss, but require careful titration to manage side effects.

Incretin drugs like Semaglutide and Tirzepatide are currently the most effective weight loss medications for older adults, often resulting in 15-25% body weight loss. They work by mimicking gut hormones to reduce hunger. Doctors usually start with a low dose to minimize side effects like nausea and gradually increase it.

Achieving a 5% weight loss over one year results in substantial direct medical cost savings for people with obesity, with savings increasing alongside higher obesity severity.

You do not need to achieve massive weight loss to see financial benefits. Losing just 5% of your body weight within a year can lead to substantial savings in direct medical costs, with the greatest savings seen in those with higher obesity severity (Class II and III). Focus on achieving this modest, sustainable reduction.

Phentermine/topiramate and naltrexone/bupropion are effective alternative pharmacotherapies for weight loss (4-10%) in patients without cardiovascular contraindications, offering oral administration options.

If you cannot take or afford weekly injections, oral medications like phentermine/topiramate or naltrexone/bupropion are effective alternatives. They typically result in 4-10% weight loss. Side effects like nausea or insomnia are common but often improve over time, especially if you start with a low dose and increase slowly. These are not suitable if you have heart disease, high blood pressure, or a history of seizures.

Resistance training over a full range of motion is superior to partial range of motion for hypertrophy.

To build the most muscle, perform your exercises through a full range of motion. Partial reps are less effective for hypertrophy.

Tirzepatide (5, 10, or 15 mg once weekly) provides significantly longer continuous time in glycaemic control (HbA1c <7.0% and ≤6.5%) and sustained body weight reduction (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies in patients with type 2 diabetes.

For patients with Type 2 Diabetes, tirzepatide (5, 10, or 15 mg once weekly) offers significantly longer periods of stable blood sugar (HbA1c <7.0%) and sustained weight loss (≥5%) compared to placebo, semaglutide 1 mg, and insulin therapies. This suggests that tirzepatide may provide more durable disease management with fewer hypoglycaemic events than insulin.

High effort (proximity to failure) is a necessary condition for muscle hypertrophy, particularly when using low loads, whereas high-load training inherently generates high effort.

To build muscle, you must train with high effort, meaning you should stop 0-3 reps before you physically cannot complete another repetition. This is true whether you are lifting heavy weights or light weights. If you use light weights, you MUST go close to failure to get similar growth as heavy weights.

Resistance exercise can be effectively performed using bodyweight, provided the intensity and effort are sufficient to overload the neuromuscular system.

You can build strength and muscle using only your body weight. Ensure you are performing exercises that challenge you (e.g., push-ups, squats) with sufficient intensity. If bodyweight exercises become too easy, increase the difficulty (e.g., elevate feet) rather than assuming you need weights.

Isometric resistance training (e.g., handgrip) produces greater systolic blood pressure reductions (up to 8 mm Hg) than aerobic or dynamic resistance training.

Incorporate isometric exercises, such as handgrip training, into your routine. Perform 3 sessions per week, holding 30-40% of your maximum grip strength for 2 minutes with 1-minute rests, repeated 4 times. This specific type of exercise can lower blood pressure more effectively than aerobic or dynamic resistance training alone.

Sustained weight loss of at least 10% from maximum weight is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce cardiovascular events.

If you are at moderate or high cardiovascular risk, aim to lose 10% of your maximum lifetime weight. This is a higher bar than the 5% target for lower-risk individuals, but it is the threshold shown to significantly reduce the risk of heart attacks and strokes. Discuss with your doctor if pharmacotherapy (like GLP-1s) or surgery is appropriate to help you reach this target.

Lifestyle interventions, specifically achieving 7-10% body weight loss through caloric restriction and physical activity, are the cornerstone for reducing cardiovascular risk and improving hepatic steatosis in patients with metabolic-associated steatotic liver disease (MASLD).

To lower your heart and liver risk, aim to lose 7-10% of your body weight through a calorie-controlled diet (cut 500-1000 calories daily) and regular exercise (150 minutes of moderate activity weekly). Prioritize whole grains, lean proteins, and healthy fats (Mediterranean style), while eliminating sugary drinks and trans fats. Stop drinking alcohol completely, as it harms the liver more than it helps the heart in this condition. Work with a healthcare team to make these changes sustainable.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) produce substantial weight loss and metabolic improvements in patients with severe mental illness experiencing antipsychotic-induced weight gain, without exacerbating psychiatric symptoms.

For patients with severe mental illness struggling with antipsychotic-induced weight gain, GLP-1 receptor agonists like semaglutide offer a highly effective treatment option that reduces weight significantly without worsening mental health symptoms. While side effects like nausea are common, they are often mild and transient. The main barrier is often cost and insurance coverage, so patients and providers should advocate for access to these medications as a standard part of care for this population.

Anti-obesity medications (AOMs) cause disproportionate loss of lean mass (skeletal muscle), which may worsen frailty and functional capacity in heart failure patients, necessitating concurrent resistance training and protein intake.

When using GLP-1 or GLP-1/GIP medications for heart failure, be aware that you will lose muscle mass along with fat. To protect your strength and function, you MUST combine these medications with resistance training and ensure adequate protein intake. Monitor your functional capacity closely.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that promotes weight loss and glycemic control through synergistic mechanisms including increased glucose-dependent insulin secretion, reduced glucagon, delayed gastric emptying, and increased satiety.

Tirzepatide is a powerful, weekly injectable medication for diabetes and obesity that works by mimicking hormones to control blood sugar and reduce appetite. It requires a prescription, medical supervision, and lifestyle changes (diet/exercise). Using it without medical oversight for aesthetic reasons is dangerous and contributes to drug shortages and fraud.

Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.

Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.

Isometric training at long muscle lengths produces similar quadriceps femoris hypertrophy to full range of motion isotonic training in resistance-trained individuals.

If you want to build quad size, you don't necessarily need to do full squats or leg presses. You can use isometric holds at the bottom of the movement (long muscle length) for 30 seconds per set. Do 3-5 sets per session, twice a week, progressively adding sets over 6 weeks. This will build muscle just as well as traditional dynamic leg exercises, provided you are already trained in resistance training.

Adherence to a healthy vegan diet results in greater improvements in overall diet quality (HEI-2015) compared to a healthy omnivore diet, driven by higher intakes of fiber, legumes, and vegetables and lower intakes of added sugars and refined grains.

If you switch to a vegan diet, focus on increasing vegetables, legumes, nuts, seeds, and whole grains while reducing added sugars and refined grains. This study shows that a well-structured vegan diet can improve overall diet quality more than a healthy omnivore diet. Start with delivered meals or meal planning support to build skills, then transition to self-prepared meals. Ensure you monitor Vitamin B12 levels as intake drops without animal products.

Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.

If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.

Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.

Semaglutide is a highly effective weekly injection for weight loss, averaging 10-12% loss in clinical trials. It is more effective than older drugs like Orlistat or Phentermine-Topiramate and also improves heart health markers. It requires weekly injections and titration to manage side effects.

Maintaining a higher proportional energy intake from protein (by limiting discretionary foods) is associated with lower total energy intake and better 12-month weight loss maintenance, whereas diluting protein with high fat/carbohydrate leads to increased energy intake and weight regain via the protein leverage mechanism.

To maintain weight loss, prioritize foods that keep your protein percentage high relative to fats and carbs. Avoid 'discretionary' foods (sweets, processed snacks) which dilute protein concentration and trigger overeating. You don't necessarily need to increase total protein grams, but you must increase its proportion in your diet by reducing low-protein energy sources.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.

If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.